glp 1 new drug GLP-1 Agonists: A Comprehensive Overview Comparing Ozempic, Wegovy and Other

Germany, the UK, France, and Scandinavia are the primary European GLP-1 markets, with strong diabetes prescribing supported by national guideline recommendations and health insurance coverage

In concrete numbers, this means that 1 in 8 American adults has been estimated to have tried the drug to date

These results are comparable to those observed in individuals receiving GLP-1R agonists and the co-agonists tirzepatide and retatrutide for the treatment of T2DM (Lorenz et al

An exploratory signal suggested a potential lower risk of heart failure hospitalization with semaglutide compared to dapagliflozin

doi: 10.1530/acta.0.0440139